ArticleBMC infectious diseases2026
Drug resistance patterns and associated risk factors in pulmonary tuberculosis patients from selected hospitals in Ghana.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-resistant tuberculosis (TB) poses a major challenge to global TB control. Understanding local resistance patterns and their determinants is essential for designing effective control strategies. This study investigated the prevalence and risk factors associated with drug-resistant Mycobacterium tuberculosis among patients with pulmonary TB in selected hospitals across Ghana. METHODOLOGY: This prospective, multi-center, cross-sectional study was conducted in selected hospitals in the southern and northern parts of Ghana between August 2019 and August 2020. Sputum samples were collected from tuberculosis-suspected patients and screened for Mycobacterium tuberculosis using GeneXpert MTB/RIF. GeneXpert-positive samples were cultured in Mycobacterial Growth Indicator Tube (MGIT). M. tuberculosis isolates were tested for susceptibility to first-line anti-tuberculosis drugs using MGIT. TB risk factors and demographic data were collected using a structured questionnaire. Data were analyzed using SPSS version 26.
resultsOf 167 M. tuberculosis isolates, 17.4% showed resistance to at least one first-line drug. Resistance to rifampicin, isoniazid, streptomycin, and ethambutol was 13.2%, 9.0%, 6.0%, and 5.4%, respectively. Mono-resistance (resistance to only one first-line drug) occurred in 8.4% of isolates, while MDR/RR-TB accounted for 13.2%. Most MDR-TB cases (12.0%) were from new patients. Resistance rates were significantly higher in southern Ghana sites than in northern sites. Southern location was the only independent predictor of resistance (aOR 4.04; 95% CI: 1.57–10.37; p = 0.004), with no associations for sex, age, or alcohol use.
conclusionThe relatively high prevalence of rifampicin and isoniazid resistance, along with an MDR/RR-TB rate of 13.2%, underscores a concerning public health challenge. The regional disparity observed suggests the need for enhanced surveillance, targeted interventions, and strengthened treatment monitoring in southern Ghana to curb the spread of resistant TB strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.